Life Changing Daily Pill that Fights Cancer and Autoimmune Diseases
Invest Now for a Limited Time

Trethera shares exciting progress in its research on optic neuritis and autoimmune diseases. After the FDA granted Orphan Drug designation for TRE-515 in optic neuritis and acute disseminated encephalomyelitis (ADEM), Trethera began building deeper connections with patient communities.

In this talk, Trethera leaders discuss:

  • The scientific promise behind TRE-515 in rare autoimmune conditions
  • FDA recognition through orphan drug status
  • Insights into patient experiences and needs
  • How patient partnerships shape the company’s development strategy

This presentation highlights the intersection of groundbreaking science and real-world patient impact.